The Conundrum of Online Prescription Drug Promotion; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”

Document Type: Commentary

Author

Moffort College of Business, University of Northern Colorado, Greeley, CO, USA

Abstract

This commentary discusses pertinent issues from Hyosun Kim’s paper on online prescription drug promotion. The study is well-designed and the findings highlight some of the consequences of the Food and Drug Administration’s (FDA’s) decision to deregulate online advertising of prescription drugs. While Kim’s findings confirm some of the early concerns, they also provide a perspective of implementation challenges in the everchanging technological environment.

Keywords

Main Subjects


  1. Hyosun K. Trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of FDA warning letters. Int J Health Policy Manag. 2015;4(12):813-822. doi:10.15171/ijhpm.2015.157
  2. Arnold DG, Oakley J. The politics and strategy of industry self-regulation: the pharmaceutical industry's principles for ethical direct-to-consumer advertising as a deceptive blocking strategy. J Health Polit Policy Law. 2013;38(3):505-544. doi:10.1215/03616878-2079496
  3. Perrin A. Social Media Usage: 2005-2015. Pew Internet & American Life Project; 2015.
  4. United States, Government Accountability Office. Prescription drugs : improvements needed in FDA's oversight of direct-to consumer advertising : report to congressional requesters. Washington, DC: GAO; 2006.
  5. Angell M. The truth about the drug companies : how they deceive us and what to do about it. New York: Random House Trade Paperbacks; 2005.
  6. Frosch D, Krueger P, Hornik R, Cronholm P, Barg F. Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising. Ann Fam Med. 2007;5(1):6-13.
  7. Cox A, Cox D. A defense of direct-to-consumer prescription drug advertising. Business Horizons. 2010;53(2):221-228. doi:10.1016/j.bushor.2009.11.006
  8. Arnold DG, OAkley A. The politics and strategy of industry self-regulation: the pharmaceutical industry's principles for ethical direct-to-consumer advertising as a deceptive blocking strategy.  J Health Polit Policy Law. 2013;38(3):505-544. doi:10.1215/03616878-2079496
  9. Frosch DL, Grande D, Tarn DM, Kravitz RL. A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising. Am J Public Health. 2010;100(1):24-32. doi:10.2105/AJPH.2008.153767
  10. Ahn H, Park J, Haley E. consumers' optimism bias and responses to risk disclosures in direct‐to‐consumer (DTC) Prescription drug advertising: the moderating role of subjective health literacy. J Consum Aff. 2014;48(1):175-194. doi:10.1111/joca.12028
  11. Lynch HF, Cohen IG. FDA in the Twenty-First Century : The Challenges of Regulating Drugs and New Technologies. New York: Columbia University Press; 2015.